Browsing by Author "Akay, Olga Meltem"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Brentuximab Vedotin And Bendamustine: An Effective Salvage Therapy For Relapsed Or Refractory Hodgkin Lymphoma Patients
    (2022) Ulu, Bahar Uncu; Dal, Mehmet Sinan; Hindilerden, Ipek Yonal; Akay, Olga Meltem; Mehtap, Ozgur; Buyukkurt, Nurhilal; Hindilerden, Fehmi; Gunes, Ahmet Kursad; Yigenoglu, Tugce Nur; Basci, Semih; Cakar, Merih Kizil; Acik, Didar Yanardag; Korkmaz, Serdal; Ulas, Turgay; Ozet, Gulsum; Ferhanoglu, Burhan; Nalcaci, Meliha; Altuntas, Fevzi; https://orcid.org/0000-0002-0895-4787; 34514960; AAE-1457-2021
    The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m(2) B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients' median age at BvB initiation was 33 (range: 18-76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2-11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.
  • No Thumbnail Available
    Item
    An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
    (2021) Sevindik, Omur Gokmen; Ozkurt, Zubeyde Nur; Boga, Can; Besisik, Sevgi Kalayoglu; Ipek, Yildiz; Geduk, Ayfer; Harmandali, Aybuke; Salihoglu, Ayse; Sahin, Handan Haydaroglu; Sonmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Yuksel, Meltem Kurt; Maral, Senem; Ekinci, Omer; Kirkizlar, Hakki Onur; Tekinalp, Atakan; Demir, Nazli; Merter, Mustafa; Saydam, Guray; Alacacioglu, Inci; Yegin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Ozsan, Guner Hayri